Search
Ibudilast
go.drugbank.com/drugs/DB05266InvestigationalIbudilast is an anti-inflammatory and neuroprotective oral agent which shows an excellent safety profile at 60 mg/day and provides significantly prolonged time-to-first relapse and attenuated brain volume
GEM-231
go.drugbank.com/drugs/DB05798InvestigationalMonoclonal antibodies are made in the laboratory and can locate and bind to cancer cells.
Bafilomycin A1
go.drugbank.com/drugs/DB06733ExperimentalThe bafilomycins refer to a category of toxic macrolide antibiotics that are derivatives of Streptomyces griseus.
Octacosanol
go.drugbank.com/drugs/DB11220InvestigationalNutraceuticalThis high–molecular-weight organic compound is the main component of a natural product wax extracted from plants [A27245]. 1-octacosanol is reported to possess cholesterol-lowering effects, antiaggregatory
Nizubaglustat
go.drugbank.com/drugs/DB21603InvestigationalNizubaglustat is under investigation in clinical trial NCT07054515 (A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type
Vicadrostat
go.drugbank.com/drugs/DB21693InvestigationalVicadrostat is under investigation in clinical trial NCT07064473 (A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular
Alphameprodine
go.drugbank.com/drugs/DB01499ExperimentalIllicitThe stereoisomer betameprodine is similarly classified, however alphameprodine is more widely used (both are referred to as Meprodine). Alphameprodine is a structural analogue of meperidine.
Betameprodine
go.drugbank.com/drugs/DB01552ExperimentalIllicitThe stereoisomer alphameprodine is similarly classified, and was more widely used (both are referred to as Meprodine). Betameprodine is a structural analogue of meperidine.
Gaboxadol
go.drugbank.com/drugs/DB06554InvestigationalGaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing
Osanetant
go.drugbank.com/drugs/DB04872InvestigationalThis follows an earlier decision to discontinue development of eplivanserin for schizophrenia.